News

Antharis Therapeutics CEO Dr. Raphael Ribeiro-Pinaud Named Among “Most Impactful CEOs of the Year 2024" by CIO Today

March 18, 2024

SAN DIEGO, CA – March 18, 2024 – Antharis Therapeutics, a biopharmaceutical company developing a leading portfolio of oncology immunotherapeutics, is proud to announce that Dr. Raphael Ribeiro-Pinaud, CEO and Chairman, has been recognized as one of the “Visionary Vanguard: Most Impactful CEOs of the Year 2024”, by CIO Today. The feature and cover article describes Dr. Ribeiro-Pinaud's journey of perseverance, leadership, and transformative impact in the biotech sector.

‍

The article details Dr. Ribeiro-Pinaud's inspiring path from modest origins in Brazil to becoming a leading figure in biopharmaceutical innovation. Driven by a relentless pursuit of scientific excellence and patient-centric solutions, Dr. Ribeiro-Pinaud founded and, since its inception, has shaped Antharis Therapeutics into a top emerging biopharmaceutical company specializing in the development of groundbreaking therapies for cancer. His leadership philosophy is built on resilience, determination, and a visionary outlook, all of which have been instrumental in advancing the company’s mission of transforming healthcare through cutting-edge biotechnology.

‍

Dr. Ribeiro-Pinaud’s story is not just about personal and professional achievements, but about cultivating a culture of innovation, collaboration, and patient-centered care at Antharis. His commitment to empowering teams and fostering a dynamic workplace environment has driven the development of life-changing therapies that address critical medical needs. This recognition by CIO Today underscores his influence and dedication to pushing the boundaries of possibility and potentially transforming the biotech industry.

‍

To read the full article and learn more about Dr. Ribeiro-Pinaud's journey and his leadership at Antharis Therapeutics, visit CIOToday.

‍

‍

About Antharis Therapeutics‍

Antharis Therapeutics is a leading biopharmaceutical company focused on developing monoclonal antibody therapies for oncology and other critical medical fields. The company’s innovative approach to cancer treatment harnesses the power of immuno-oncology, enhancing the body’s immune response to fight cancer effectively. With a robust pipeline of therapies and a multidisciplinary team of experts, Antharis is dedicated to transforming the future of healthcare by delivering safe, effective, and life-changing treatments to patients worldwide. For more information, please visit www.antharistherapeutics.com.